GoodRx Dismisses PwC, Appoints KPMG as New Independent Auditor

GoodRx Holdings replaced PricewaterhouseCoopers with KPMG LLP as its independent auditor, with the Santa Monica-based prescription savings company's Audit and Risk Committee making the call on March 14 and CFO Christopher McGinnis signing the Form 8-K disclosure four days later.

KPMG takes over for the fiscal year ending December 31, 2026. The switch came without the kind of red flags that typically make auditor changes unsettling for investors: PwC's audit reports on GoodRx's 2024 and 2025 consolidated financial statements carried no adverse opinions, disclaimers, or qualifications, and the company reported no disagreements or reportable events with PwC through the date of the committee vote.

GoodRx also disclosed it had not consulted KPMG on any accounting or auditing matters before the appointment, meaning this was a clean handover rather than a situation where the incoming firm had already been advising informally on contested issues. That detail matters because undisclosed pre-appointment consultations have historically been a source of auditor independence questions at other companies.

The filing, a Current Report on Form 8-K submitted to the Securities and Exchange Commission and signed by McGinnis in his capacity as Chief Financial Officer and Treasurer, included a letter from PricewaterhouseCoopers to the SEC dated March 18, 2026, attached as Exhibit 16.1. That letter's contents were not summarized in the filing itself; the full text sits on SEC EDGAR. GoodRx's filing carries Commission File Number 001-39549 and lists its principal offices at 2701 Olympic Boulevard in Santa Monica.

What the filing does not address is why GoodRx made the change. No strategic rationale, fee consideration, or rotation policy was cited in the materials submitted to the SEC. For KPMG, the engagement adds a NASDAQ-listed healthcare technology company to its audit portfolio at a moment when the firm, like its Big 4 peers, is navigating significant pressure to demonstrate audit efficiency gains tied to AI tooling. Whether any of that factored into GoodRx's selection process remains undisclosed.